Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The company's product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimer's disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for Phase 2 trial of AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.